Research programme: SARS CoV-2 inhibitors - Medivir AB/SciLifeLab
Alternative Names: Research programme: coronavirus inhibitors - Medivir AB/SciLifeLab; Research programme: COVID-19 inhibitors - Medivir AB/SciLifeLabLatest Information Update: 28 Aug 2024
At a glance
- Originator Medivir AB
- Developer Medivir AB; SciLifeLab
- Class Antivirals
- Mechanism of Action Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for research development in COVID-2019-infections in Sweden
- 06 Jul 2020 Medivir AB and SciLifeLab agree to co-develop potential SARS CoV-2 inhibitors in Sweden for COVID-2019 infections
- 06 Jul 2020 Early research in COVID-2019 infections in Sweden (unspecified route)